Akari Therapeutics (AKTX) investor relations material

Executive summary

• Focused on developing next-generation antibody-drug conjugates (ADCs) with a proprietary PH1 payload, targeting solid tumors and leveraging immune activation for cancer therapy.

• Lead candidate AKTX-101 is in preclinical development, with IND-enabling activities underway and a projected Phase 1 trial start in early 2027.

• Completed the acquisition of Peak Bio in November 2024, shifting strategic focus to the ADC platform and suspending legacy programs.

• No commercial products or product revenue to date; operations funded primarily through equity and debt financings.

Financial highlights

• Net loss for 2025 was $17.3 million, a decrease from $19.8 million in 2024, primarily due to lower operating expenses post-merger.

• Research and development expenses decreased by 60% to $2.8 million in 2025, reflecting program reprioritization.

• General and administrative expenses were $9.3 million in 2025, down 4% from 2024, with $2.5 million in non-cash stock-based compensation.

• Impairment loss of $5.2 million recognized on PHP-303 IPR&D asset due to resource reprioritization.

• Cash balance at year-end 2025 was $5.2 million; accumulated deficit reached $264.5 million.

• Multiple equity and debt financings in 2025 raised approximately $14.2 million in net proceeds.

Outlook and guidance

• Existing cash is expected to fund operations into April 2026; additional capital will be required to continue operations and advance clinical programs.

• Plans to seek further funding through equity/debt offerings, partnerships, or asset sales.

• AKTX-101 anticipated to enter clinical trials in Q1 2027, with ongoing IND-enabling and GMP manufacturing activities.